Format

Send to

Choose Destination
See comment in PubMed Commons below
Semin Thromb Hemost. 2012 Oct;38(7):661-6. doi: 10.1055/s-0032-1326789. Epub 2012 Oct 9.

Warfarin pharmacogenetics: does more accurate dosing benefit patients?

Author information

1
Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, Missouri, USA. eby@wustl.edu

Abstract

After a decade of clinical investigation, pharmacogenetic-guided initial dosing of warfarin is at a crossroads. Genotypes for two single nucleotide polymorphisms (SNPs) in the cytochrome P 450 2C9 gene, affecting warfarin metabolism, and one SNP in vitamin K reductase complex 1 gene, affecting warfarin sensitivity, account for approximately 30% of therapeutic warfarin dosing variability in whites and Asians. Incorporating this genetic information, along with patient's age, body size, and other clinical information improves the accuracy of initial warfarin dosing. Currently, there is insufficient evidence to support the clinical benefits and cost effectiveness of routine warfarin pharmacogenetics. Results from ongoing international randomized clinical trials should provide clarity about the place of warfarin pharmacogenetics in personalized medicine.

PMID:
23047421
PMCID:
PMC4407810
DOI:
10.1055/s-0032-1326789
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Georg Thieme Verlag Stuttgart, New York Icon for PubMed Central
    Loading ...
    Support Center